Targeting Tissue Factor Pathway Inhibitor with concizumab to improve haemostasis in patients with Glanzmann thrombasthenia: an in vitro study

2024-9-1

Pathogenic but sweet: factor VIII inhibitor hits the hot spot

2024-9-1

“2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19”: comment from Flumignan et al.

2024-9-1

The changing face of cerebral venous sinus thrombosis – emerging new causes and treatments

2024-9-1

Endothelial Colony Forming Cells in the spotlight, insights into the pathophysiology of von Willebrand Disease and rare bleeding disorders.

2024-9-1

Patency and reflux in relation to post-thrombotic syndrome: a subanalysis of the Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome trial

2024-9-1

Utility of the Modified Ottawa Score for Identification of More Preferable Candidates of Extended Anticoagulation therapy in Cancer-associated Isolated Distal Deep Vein Thrombosis: Insight from the ONCO DVT Study

2024-9-1

Professor Victor S. Blanchette, MA, MB, Bchir (Cantab), FRCP(C), FRCP (1945-2024)

2024-9-1

Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines

2024-9-1

Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hot-spot on the C1 domain

2024-9-1

ISTH News and Updates: Join the ISTH Today

2024-9-1

Low VWF – unravelling an enigma wrapped in a conundrum.

2024-9-1

Estimation of Gestational Age-Specific Reference Intervals for Coagulation Assays in a Neonatal Intensive Care Unit Using Real-World Data

2024-9-1

Plasma levels of Complement components C5 and C9 are associated with thrombin generation

2024-9-1

Clinical validation and application of targeted long-range PCR and long-read sequencing-based analysis for haemophilia: experience from a haemophilia treatment centre in China

2024-9-1

Treatment of Atrial Fibrillation and Venous Thromboembolism with Factor Xa Inhibitors in Severely Obese Patients

2024-9-1

Development of an assay using a modified coagulation factor V to measure protein S activity

2024-9-1

The use of DOACs in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia

2024-9-1

Lack of FVIII detection in humans and dogs with an intron-22 inversion challenges hypothesis regarding inhibitor risk

2024-9-1

Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study

2024-9-1

The management of liver disease in people with congenital bleeding disorders: guidance from EAHAD, EHC, ISTH, WFH

2024-9-1

Issue Information

2024-9-1

Factors Associated with Venous Thromboembolism Pharmacoprophylaxis Initiation in Hospitalized Medical Patients: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study

2024-9-1

VIRAL COAGULATION: Pushing the Envelope

2024-9-1

Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms

2024-9-1

Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

2024-9-1

“2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19”: reply

2024-8-23

Cutting the Gordian knot of neutrophil extracellular traps research

2024-8-23

The enigma of factor XII surface binding

2024-8-23

Gene therapy for people with Haemophilia B: a proposed care delivery model in Italy

2024-8-1

Comprehensive functional characterization of a novel ANO6 variant in a new patient with Scott syndrome

2024-8-1

Sensitivity and Specificity of Strategies to Identify Patients with Haemostasis Abnormalities Leading to an Increased Risk of Bleeding Before Scheduled Intervention: the Hemorisk Study

2024-8-1

Annoucements

2024-8-1

The Historical Origins of Modern INR Targets

2024-8-1

Targeted Treatments for Vascular Malformations: Current State of the Art.

2024-8-1

ECMO aggravates platelet GPV shedding and δ-granule deficiency in COVID-19-associated acute respiratory distress syndrome

2024-8-1

“Prothrombin conversion and thrombin decay in patients with cirrhosis—role of prothrombin and antithrombin deficiencies”: comment from de Laat-Kremers et al.

2024-8-1

Unexpected bleeding with platelet phosphatidylserine exposure defect: new kindred motivates rethinking Scott syndrome

2024-8-1

“Antiphospholipid antibody solid phase–based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome”: reply

2024-8-1

Anxiety in patients with venous thromboembolism: Quantification and risk factors in a prospective cohort study

2024-8-1

Rapid and ordered cleavage of prothrombin by Hopsarin D in the absence of phospholipid membranes

2024-8-1

Early thrombus formation is required of eccentric and heterogenous neointimal hyperplasia under disturbed flow

2024-8-1

Application of genetic testing for the diagnosis of von Willebrand disease

2024-8-1

Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism.

2024-8-1

“Prothrombin conversion and thrombin decay in patients with cirrhosis—role of prothrombin and antithrombin deficiencies”: comment

2024-8-1

Venous thromboembolism and estrogen—dance with the devil in thrombosis medicine

2024-8-1

Hepatocyte-independent PAR1-biased signaling controls liver pathology in experimental obesity

2024-8-1

Development of a structured follow-up model for patients with pulmonary embolism: The Attend-PE model

2024-8-1

Targeting cargo to an unconventional secretory system within megakaryocytes allows the release of transgenic proteins from platelets

2024-8-1

Novel GPIb-independent platelet aggregation induced by botrocetin: Implications for diagnosis and antithrombotic therapy

2024-8-1